Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Hemophilia
More »

  • Scaleup Issues for Single Use and Steel
    ... The facility is currently committed to producing a recombinant antihemophilic Factor VIII therapy for the treatment of hemophilia A patients. In preparation for their move into ...
    10-15-2013
  • Catalyst, Isu Abxis to Develop Hemophilia B Candidate
    FIX-NG (CB 2679d) for the prevention and treatment of bleeding in hemophilia B patients. ... FIX-NG's development and ultimately provide improved therapy for hemophilia B patients." ...
    10-9-2013
  • Young Companies in the Money: 25 Firms to Watch
    ... regulatory approval in Europe, as well as the co-development of a gene therapy for hemophilia B. Financing leaders: Chiesi Farmaceutici (equity financing) 5 , Coller Capital ...
    10-2-2013
  • Amunix, Janssen Expand XTEN Collaboration
    Amunix is also working with Biogen Idec in hemophilia, and with several other undisclosed partners in various other therapeutic areas. Janssen exercises option to develop an ...
    8-14-2013
  • Adimab Licenses Antibody Platform to GSK, Biogen Idec
    with Biogen Idec by licensing to the biotech giant its antibody platform for use in Biogen Idec's targeted therapeutic areas, which include multiple sclerosis and hemophilia. ...
    7-26-2013
  • Drug Candidates on Trial
    ... to assess the safety of ORMD-0801. Hemophilia A > Bayer HealthCare started to enroll ... its investigational compound BAY94-9027 for the treatment of hemophilia A in children. ...
    7-22-2013
  • Biogen Idec, Sobi Cite Promising Phase III Results for Hemophilia...
    factor VIII candidate Eloctate for hemophilia A could potentially reduce the number ... major surgeries in nine patients with hemophilia A, by showing high efficacy during ...
    7-5-2013
  • FDA Approves Baxter's Rixubis for Hemophilia B
    Making it the first new recombinant factor IX approved for hemophilia B in more than 15 years, FDA has approved Baxter International's Rixubis for use in hemophilia B patients 16 and ...
    7-1-2013
  • Gene Editing to Treat Genetic Diseases, Part II
    ... using TALEN technology could help treat other genetic diseases where a few gene mutations are responsive, such as sickle cell diseases, hemophilia, or other muscular dystrophies. ...
    6-20-2013
  • Novo Nordisk Reports Promising Phase III Results for Hemophilia...
    III trial for N9-GP (glycopegylated recombinant factor IX), for hemophilia B patients. ... a paradigm shift in the treatment of hemophilia B." Novo Nordisk said it expects the ...
    5-17-2013
  • Ipsen Enlists PeptiDream in Search for Therapeutic Peptides
    This deal appears to be potential good news for Ipsen, which recently, along with bankrupt company Inspiration Biopharmaceuticals, sold its rights to hemophilia drugs OBI-1 to ...
    4-10-2013
  • Is This Gene Therapy's Breakout Moment?
    to develop and commercialize potential hemophilia B treatments using gene therapy ... an AAV8 vector in up to 16 adults with Hemophilia B. Pharma is attracted to low-lying ...
    4-1-2013
  • A Good Day for Milestones
    Factor VIII (TheraPEG-FVIII) to treat hemophilia A. Celtic subsequently exercised its ... to 72 hours in a preclinical model of naturally occurring hemophilia A, the firms report. ...
    3-7-2013
  • Is This Gene Therapy's Breakout Moment?
    ... to develop and commercialize potential hemophilia B treatments using gene therapy ... an AAV8 vector in up to 16 adults with hemophilia B. Pharma is attracted to low-lying ...
    3-4-2013
  • Genome Editing for R&D and Therapeutics
    ... a range of monogenic diseases such as hemophilia and lysosomal storage disorders like ... An example is our program that targets hemophilia in which the liver fails to produce ...
    3-1-2013
  • More »

    Journal Articles

  • Complete Correction of Hemophilia A with Adeno-Associated Viral...
    Hui Lu, Lingxia Chen, Jinhui Wang, Bernd Huack, Rita Sarkar, Shangzhen Zhou, Ray Xu, Qiulan Ding, Xuefeng Wang, Hongli Wang, Weidong Xiao
    Human Gene Therapy and Part B: Methods
    Complete Correction of Hemophilia A with Adeno-Associated Viral Vectors Containing a Full-Size Expression Cassette Human Gene Therapy and Part B: Methods Abstract Hemophilia A is ...
  • Recent Progress in Gene Therapy for Hemophilia
    Marinee K. Chuah, Nisha Nair, Thierry VandenDriessche, Nair Nisha
    Human Gene Therapy and Part B: Methods
    Recent Progress in Gene Therapy for Hemophilia Human Gene Therapy and Part B: Methods Abstract Hemophilia A and B are X-linked monogenic disorders caused by deficiencies in ...
  • Sustained Phenotypic Correction of Canine Hemophilia B After...
    Nicola Brunetti-Pierri, Timothy C. Nichols, Stephanie McCorquodale, Elizabeth Merricks, Donna J. Palmer, Arthur L. Beaudet, Philip Ng
    Human Gene Therapy and Part B: Methods
    Sustained Phenotypic Correction of Canine Hemophilia B After Systemic Administration of ... helper-dependent adenoviral (HDAd) vector-mediated gene therapy in the hemophilia B dog. ...
  • Increased Soluble Fas in HIV-Infected Hemophilia Patients with...
    Volker Daniel, Caner Süsal, Rolf Weimer, Rainer Zimmermann, Angela Huth-Kühne, Gerhard Opelz
    AIDS Research and Human Retroviruses
    Increased Soluble Fas in HIV-Infected Hemophilia Patients with CD4 + and CD8 + Cell Count ... in long-term surviving HIV-infected hemophilia patients, most of whom were receiving ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Balancing Family and Career for Women Ph.D.s

Which changes made to academic culture are most likely to encourage women researchers to stay?

Suggest a Poll